FDA Avoids Funding Cut In Latest Cures Draft
This article was originally published in The Pink Sheet Daily
Executive Summary
While NIH sees more than a $1 billion cut in added funding, FDA’s portion remains intact as bill nears House vote and sponsors tweak the ‘pay-fors.’
You may also be interested in...
Congressional ‘Cures’ Debate Shifts To FDA Funding
House Democrats say FDA will need more money to be able to handle the responsibilities in the draft bill, while the agency worries reviews could slow without more resources.
FDA Lands Duke’s Califf As Top Deputy, Potential Next Commissioner
Renowned cardiologist and clinical trialist Robert Califf will join FDA in February as deputy commissioner for medical products and tobacco.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.